2-溴-6-乙烯基苯酚 | 811867-45-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-6-乙烯基苯酚
• 英文名称: 2-bromo-6-vinylphenol
• 英文别名: 2-Bromo-6-ethenylphenol
• CAS: 811867-45-5
• 化学式: C₈H₇BrO
• 分子量: 199.047
• InChiKey: ITVXPWJVZSXFCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-溴-6-乙烯基苯酚 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 偶氮二甲酸二异丙酯 、 potassium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 [(2R)-8-bromo-2H-chromen-2-yl]methanol
  参考文献：
  名称：

  Optimization of the Potency and Pharmacokinetic Properties of a Macrocyclic Ghrelin Receptor Agonist (Part I): Development of Ulimorelin (TZP-101) from Hit to Clinic

  摘要：

  High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel ago fists against this G-protein coupled receptor. Early hits such as 1 (K-i = 86 nM, EC50 = 134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization. While such macrocycles are not fully rule-of-five compliant, principally due to their molecular weight and clogP, optimization of their pharmacokinetic properties proved feasible largely through conformational rigidification. Extensive SAR led to the identification of 2 (K-i = 16 nM, EC50 = 29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus. X-ray structure and detailed NMR studies indicated a rigid peptidomimetic portion in 2 that is best defined as a nonideal type-I' beta-turn. Compound 2 is 24% orally bioavailable in both rats and monkeys. Despite its potency, in vitro and in gastric emptying studies, 2 did not induce growth hormone (GH) release in rats, thus demarcating the GH versus GI pharmacology of GRLN.

  DOI：

  10.1021/jm2007062
• 作为产物：
  描述：

  2-溴苯酚 在 potassium tert-butylate 、 三乙胺 、 magnesium chloride 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成 2-溴-6-乙烯基苯酚
  参考文献：
  名称：

  Intermediates for macrocyclic compounds

  摘要：

  本发明涉及一种新型的大环化合物，其化学式为（I），以及其药用可接受的盐、水合物或溶剂化合物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所描述。该发明还涉及化合物的化学式（I），这些化合物是胃动素受体拮抗剂，可用于治疗与该受体相关的疾病以及与胃肠动力功能障碍相关的疾病。

  公开号：

  US09181298B2

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Ocera Therapeutics, Inc.

  公开号：US20180110824A1

  公开（公告）日：2018-04-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，已经证明是生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
• Cobalt(III)-Catalyzed [5 + 1] Annulation for 2<i>H</i>-Chromenes Synthesis via Vinylic C–H Activation and Intramolecular Nucleophilic Addition
  作者：Ramajayam Kuppusamy、Krishnamoorthy Muralirajan、Chien-Hong Cheng

  DOI：10.1021/acscatal.6b00978

  日期：2016.6.3

  new cobalt-catalyzed phenolic OH-assisted C–H functionalization of 2-vinylphenols with allenes to give various 2H-chromenes is described. It is the first time that allenes are used as the coupling partners in the cobalt-catalyzed C–H activation reactions. In most cases, cobalt-catalyzed oxidative annulation of arenes with alkenes or alkynes via C–H activation gave [4 + 2] or [3 + 2] cyclization products

  描述了一种新的钴催化的苯酚OH辅助的2-乙烯基苯酚与丙二烯的CH官能化反应，得到各种2 H-色烯。这是艾伦首次在钴催化的CH活化反应中用作偶联伙伴。在大多数情况下，芳烃与钴或炔烃的钴催化氧化环化通过C–H活化得到[4 + 2]或[3 + 2]环化产物，但目前的催化反应提供了氧化[5 +1]环化产物丙二烯作为一碳偶联伙伴。建议催化反应通过乙烯基的C–H活化，丙二烯插入以及不寻常的分子内区域选择性酚盐添加而进行。
• Cp*Co(<scp>iii</scp>)-Catalyzed oxidative [5+2] annulation: regioselective synthesis of 2-aminobenzoxepines <i>via</i> C–H/O–H functionalization of 2-vinylphenols with ynamides
  作者：Xiang-Lei Han、Xu-Ge Liu、E Lin、Yunyun Chen、Zhuangzhong Chen、Honggen Wang、Qingjiang Li

  DOI：10.1039/c8cc06807k

  日期：——

  A Cp*Co(III)-catalyzed [5+2] C–H annulation reaction of 2-vinylphenols with ynamides was developed. The reaction led to the efficient synthesis of valuable 2-aminobenzoxepines in high regioselectivity. Mild reaction conditions, good functional group tolerance, and moderate to good yields were observed. The synthetic utility was demonstrated by a gram-scale synthesis and further transformations of the

  开发了Cp * Co（III）催化的2-乙烯基苯酚与乙酰胺的[5 + 2] CH环化反应。该反应导致在高区域选择性下有效合成有价值的2-氨基苯并x庚因。观察到温和的反应条件，良好的官能团耐受性和中等至良好的产率。通过克规模的合成和产物的进一步转化证明了合成的效用。进行了初步的机理研究，并提出了可能的催化循环。
• Rh(III)-Catalyzed Oxidative [5 + 2] Annulation Using Two Transient Assisting Groups: Stereospecific Assembly of 3-Alkenylated Benzoxepine Framework
  作者：Wei Yi、Liping Li、Hongzhen Chen、Kuangshun Ma、Yuting Zhong、Weijie Chen、Hui Gao、Zhi Zhou

  DOI：10.1021/acs.orglett.8b02940

  日期：2018.11.2

  propargyl carbonates have been developed by using two O-containing functional groups as the traceless assisting groups (AGs). The experimental investigations together with the density functional theory (DFT) calculations revealed that this transformation involves the free OH-directed cleavage of one terminal C–H bond of the alkenyl moiety and regioselective alkyne insertion, followed by OBoc-promoted intramolecular

  通过使用两个含O的官能团作为无痕辅助基团（AGs），开发了一种易于获得的2-烯基苯酚与碳酸炔丙基酯的独特的Rh（III）催化氧化[5 + 2]环化反应。实验研究和密度泛函理论（DFT）计算表明，这种转变涉及烯基部分一个末端C–H键的自由OH定向裂解和区域选择性炔烃的插入，然后是OBoc促进的分子内亲核取代和β -H消除，其中使用烯丙基类作为活性中间体，可直接进入具有广泛底物相容性和良好官能团耐受性的3-烯基化苯并xepine骨架。
• MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME
  申请人：Hoveyda Hamid

  公开号：US20080194672A1

  公开（公告）日：2008-08-14

  The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，可以作为生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、骨骼疾病、遗传疾病、过度增生性疾病和炎症性疾病。